Professor Mark Kendall
|Professor Mark Kendall, above, and his research on the Nanopatch explained, below.|
ARC Future Fellow and Group Leader
BE (Hons) UQ, PhD UQ
Telephone: +61 7 334 64203 Email: firstname.lastname@example.org
Research: Targeting the skin for needle-free, minimally invasive vaccine delivery and diagnostics for disease
Professor Mark Kendall is the inventor of the Nanopatch, a needle-free vaccine delivery device which is under rapid research and development to product through spin-out company Vaxxas. Professor Kendall is a 2012 Rolex Laureate, recognising pioneering efforts to expand knowledge and improve human life. He co-founded Vaxxas with $15 million in capital investment - one of the largest investments in an Australian start-up biotechnology company. The Nanopatch technology has been licensed to US-based pharmaceutical company Merck & Co. Professor Kendall’s research group received the Eureka Prize for Research by an Interdisciplinary Team in 2011. Professor Kendall is an inaugural Australian Research Council Future Fellow.
Professor Kendall has key international links spanning academia and industry including the University of Oxford, where he was a lecturer; Harvard; PATH; WHO; and the University of Washington. Professor Kendall is a member of a Scientific Advisory Group sponsored by the WHO that aims to fast−track the development of needle−free vaccine delivery technology for use in poor countries. His Nanopatch technology has been licensed to US –based pharmaceutical company Merck & Co. Professor Kendall has lectured at the University of Oxford. While there, he was instrumental in building up PowderJect/PowderMed, which was sold to Pfizer for $US400 million.
Memberships, patents and funding
Professor Kendall is the recipient of more than $40 million in competitive research funding and another $33 million from industry. He edits papers in the Journal of Nanotechnology and Shock Waves Journal. Professor Kendall is the inventor of 96 patents.
Awards and plenaries
Professor Kendall is a Rolex Laureate, recognising pioneering efforts to expand knowledge and improve human life. He is the recipient of many prestigious accolades, including the The Australian Innovation Challenge in 2011. His AIBN group received the 2011 Eureka Prize for Interdisciplinary Research; and the Queensland Clinical Trial Network and Merck’s 2010 Translational Research Excellence Commercialisation Award. Professor Kendall won the Australian Society for Medical Research and Amgen’s Australia Medical Researcher Award in 2008; and was named Young Engineer of Britain 2004. He has presented at more than 90 international seminars and conferences, including the plenary at the 9th Symposium of the Lohmann Therapie-Systeme Academy (LTS) in Germany in 2012.
Key publications in the past five years
Fernando GJP, Chen X, Primero CA, Yukiko SR, Fairmaid EJ, Corbett HJ, Frazer IH, Brown LE, Kendall MAF. (2012) Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses. Journal of Controlled Release 159(2), 215-221.
Crichton ML, Donose BC, Chen X, Raphael A, Huang H, Kendall MAF. (2011) The viscoelastic, hyperelastic and scale dependent behaviour of freshly excised individual skin layers. Biomaterials 32(20), 4670-4681.
Chen X, Fernando GJP, Crichton ML, Flaim C, Yukiko SR, Fairmaid EJ, Corbett HJ, Primiero CA, Ansaldo AB, Frazer IH, Brown LE, Kendall MAF. (2011) Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization. Journal of Controlled Release 152(3), 349-355.
Corrie S, Fernando GJP, Crichton ML, Brunck MEG, Anderson CP, Kendall MAF. (2010) Surface-modified microprojection arrays for intradermal biomarker capture, with low non- specific protein binding. Lab on a Chip 10, 2655-2658.
Fernando GJP, Chen X, Prow TW, Crichton ML, Fairmaid EJ, Roberts MS, Frazer IH, Brown LE, Kendall MAF. (2010) Potent Immunity to Low Doses of Influenza Vaccine by Probabilistic Guided Micro-Targeted Skin Delivery in a Mouse Model. PLoS ONE 5(4), e10266. doi:10.1371/journal.pone.0010266.
|Professor Mark Kendall section|